



CONTACT:  
Investor Relations  
David Isserman  
877-895-5647  
[IR@nutrapharma.com](mailto:IR@nutrapharma.com)

## **NUTRA PHARMA NAMES FORMER REVCO AND ECKERD EXECUTIVE TO HEAD NEW MEDICAL DEVICE SUBSIDIARY**

**Boynton Beach, FL. – January 31, 2006 - Nutra Pharma Corp., (OTCBB: NPHC)** a biotechnology company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that it has engaged Neil Roth to act as the President of Designer Diagnostics, the Company's new wholly-owned subsidiary created for the purpose of marketing diagnostic test kits designed for the rapid isolation and identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma acquired the rights to these diagnostic test kits in a definitive agreement signed with NanoLogix, Inc. (PinkSheets: NNLX).

Neil Roth has over 30 years experience in the sales and marketing of consumer goods including pharmaceuticals and medical devices. His prior experience included senior management and top marketing positions of major multibillion-dollar companies, including: Revco, Eckerd Drugs and Thrifty Drugs. He has successfully increased sales in the companies that he has been associated with through his expertise and understanding of the creation of marketing plans into new and developing markets.

"We are very excited about the talent and experience that Neil Roth brings to Nutra Pharma and Designer Diagnostics," said Rik J Deitsch, Nutra Pharma's Chief Executive Officer. "He has a proven track record of bringing products to the hospital and commercial pharmacy marketplace. Through his leadership, we expect to realize our first revenues by the second quarter of 2006," he added.

"I am looking forward to bringing Designer Diagnostics' patented technology to market," commented Neil Roth, Designer Diagnostics' President. "This technology delivers a powerful new tool in the worldwide effort to eradicate Tuberculosis and other deadly bacterial infectious diseases. We are prepared to introduce and ship these needed products to the global market immediately," he concluded.

### **About Nutra Pharma Corp.**

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the

rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.nutrapharma.com>

*This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The information in this press release should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at [www.sec.gov](http://www.sec.gov). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.*

###